Vifor good for Q4 filing, but can it vie for market?
This article was originally published in Scrip
Vifor Pharma and Fresenius Medical Care Renal Pharma (a Galenica/Fresenius joint Venture) are planning regulatory filings for their hyperphosphataemia drug PA21 in the US, EU and Switzerland, starting in the fourth quarter and based on positive Phase III data. But if successful, the product will be entering a fairly saturated generics market, raising questions over its commercial potential.
You may also be interested in...
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.